



Specifications

Rapid Exchange

Balloon material: Nylon (3 fold)	Diameter guidewire: 0.014" / 0.36 mm	Entry profile: 0.017" / 0.43 mm
Coating: Hydrophilic - Distal shaft Silicon - Proximal shaft	Nominal pressure: 8 ATM	RBP: 16 ATM - 2.5 to 3.0 mm 14 ATM - 3.5 mm
Shaft: Max. size - 2.5 F / 0.84 mm Min. size - 2.0 F / 0.67 mm	Profile: 0.042" / 1.05 mm - 2.50 mm 0.043" / 1.09 mm - 2.75 mm 0.044" / 1.11 mm - 3.00 mm 0.045" / 1.13 mm - 3.50 mm	Usable length: 145 cm



Ordering information

Balloon diameter (mm)	Stent length / Product code				
	8 mm	14 mm	18 mm	24 mm	28 mm
2.50	DE-RA2508SM	DE-RA2514SM	DE-RA2518SM	DE-RA2524SM	DE-RA2528SM
2.75*	DE-RA2708SM	DE-RA2714SM	DE-RA2718SM	DE-RA2724SM	DE-RA2728SM
3.00	DE-RA3008SM	DE-RA3014SM	DE-RA3018SM	DE-RA3024SM	DE-RA3028SM
3.50	DE-RA3508LM	DE-RA3514LM	DE-RA3518LM	DE-RA3524LM	DE-RA3528LM

* Please check product availability *Please check product availability

Nobori®

Drug Eluting Stent



A novel approach
maintaining efficacy
without compromising safety



Every day, as healthcare professionals, you are working to ensure life and to contribute to the well-being of your patients. Every day, **Terumo Europe** provides you with the clinical systems, means and solutions to keep life flowing.

TERUMO CORPORATION
44-1, 2-chome
Hatagaya
Shibuya-ku
Tokyo 151-0072
Japan
Tel. +81/3 3374.8111
Fax +81/3 3374.8196

TERUMO EUROPE N.V.
Researchpark Zone 2 Haasrode
Interleuvenlaan 40
B-3001 Leuven
Belgium
Tel. +32/16.38.12.11
Fax +32/16.40.02.49

TERUMO EUROPE INTERVENTIONAL SYSTEMS
Immeuble Krebs
8, rue Jean-Pierre Timbaud
CS 10720
78067 Saint Quentin en Yvelines cedex
France
Tel. +33/1 39.30.95.75
Fax +33/1 39.30.95.70

TERUMO EUROPE N.V. BENELUX SALES DIVISION
Researchpark Zone 2 Haasrode
Interleuvenlaan 40
B-3001 Leuven
Belgium
Tel. +32/16.39.25.80
Fax +32/16.39.25.99

LABORATOIRES TERUMO FRANCE S.A.
Parc Ariane - Bât. Uranus
1 rue Hélène Boucher
78284 Guyancourt Cedex
France
Tel. +33/1 30.96.13.00
Fax +33/1 30.43.60.85

TERUMO DEUTSCHLAND GmbH
Zweigniederlassung Wettingen
Bahnhofstrasse 88
CH-5430 Wettingen
Switzerland
Tel. +41/56.419.10.10
Fax +41/56.419.10.11

TERUMO EUROPE ESPAÑA SL
Avda. Juan Carlos I, Nº 13 - 7ª Planta
Edificio Torre La Garena
28806 Alcalá de Henares (Madrid)
Spain
Tel. general: +34/902.10.12.98
cust. serv.: +34/902.20.31.40
Fax general: +34/902.10.13.58
cust. serv.: +34/902.10.17.57

TERUMO ITALIA SRL
Via Simone Martini 143/145
I-00142 Roma
Italy
Tel. +39/06.519.61.420
Fax +39/06.503.04.07

TERUMO EUROPE N.V.
Moscow Representative office
4, Ivana Franko St
121108 Moscow
Russia
Tel. +7/495.234.3303
Fax. +7/495.234.3303

TERUMO DEUTSCHLAND GmbH
Hauptstrasse 87
65760 Eschborn
Germany
Tel. +49/61.96.80.230
Fax +49/61.96.80.23.200

TERUMO SWEDEN AB
Nya Varvet, Byggnad 90
Sven Källfelts Gata 18
SE-426 71 Västra Frölunda
Sweden
Tel. +46/31.748.58.80
Fax +46/31.748.58.90

TERUMO DENMARK Filial of TERUMO SWEDEN AB
Tel. +45/7020.93.80
Fax +45/7020.94.80

TERUMO UK Ltd.
Tamesis, The Causeway
Egham
Surrey
TW20 9AW
United Kingdom
Tel. +44/1784.476.200
Fax +44/1784.476.201

®: Registered trademark of Terumo Corporation
Published by Terumo Europe N.V.
www.terumo.com
www.terumo-europe.com
Addresses are subject to change, please consult our website.




IST134GBC08MDV50509JE



Biolimus A9

A new limus-drug designed for stent application provides efficacy


- Powerful anti-proliferative and anti-inflammatory properties to reduce neo-intimal proliferation
- Precise release kinetics with an initial burst and sustained elution through polymer degradation for long term efficacy
- Biolimus high lipophilicity supports diffusion into the vessel wall to provide an efficient local effect



Biodegradable polymer PLA

On abluminal surface preserves endothelial function

- No drug on luminal surface enhances endothelialization
- Fully biodegradable PLA polymer eliminates chronic sensitivity and ensures complete drug release




▶ In stent late loss $0.11 \text{ mm} \pm 0.30 \text{ mm}^{(1)}$

▶ No stent thrombosis up to 2 years ^(1,2)

Open cell design stent

On a low compliant balloon for a superior deliverability

- Low compliant balloon provides optimal stent expansion
- Open cell for convenient side branch access
- Ryujin™ shaft providing outstanding crossability



Nobori Clinical Program

NOBORI PK - 20 Patients	The Pharmacokinetics of Biolimus A9 After Elution From the Nobori Stent in Patients With Coronary Artery Disease
NOBORI CORE - 107 Patients	Comparison of Nobori – Biolimus A9 Eluting Stent versus Cypher –Sirolimus Eluting Stent
NOBORI CORE - Endothelial study 43 patients	Comparison of endothelial function of Nobori – Biolimus A9 Eluting Stent versus Cypher –Sirolimus Eluting Stent
NOBORI 1 - 363 patients	Comparison of Nobori – Biolimus A9 Eluting stent versus Taxus-Paclitaxel Eluting stent (surrogate endpoint-In-stent Late Loss)
NOBORI JAPAN - 300 patients	Comparison of Nobori – Biolimus A9 Eluting Stents versus Cypher –Sirolimus Eluting Stents (clinical endpoint-TVF)
NOBORI 2 - 3000 patients	A Prospective, Multi-center, Observational study of the Nobori™ Drug Eluting Stent System

1. Chevalier B et al.: Randomised comparison of Nobori®, Biolimus A9-eluting coronary stent with a Taxus®, Paclitaxel eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. *EuroInterv* 2007; 2:426-34

2. Definite and probable stent thrombosis according to ARC definitions : Cutlip D. et al. *Circulation* 2007